Trial Profile
An independent pilot study to identify predictors of response to therapy with ipilimumab in patients with metastatic melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 24 Sep 2015 New trial record